We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Multiplex PCR Kit Provides Detection of Microbial Genotyping, Mutations, and Microsatellites

By LabMedica International staff writers
Posted on 03 Aug 2011
A new polymerase chain reaction (PCR) system is designed for rapid and sensitive multiplex PCR that allows researchers to amplify several targets in one PCR run. The kit provides fast reaction times and comes with a preoptimized protocol, delivering effective results on the first attempt.

The master mix included with the Multiplex PCR Plus kit contains the enzyme HotStarTaq Plus DNA polymerase, as well as a balanced combination of salts and additives, which increases multiplex reaction specificity and ensures comparable efficiencies for all primers in the PCR reaction. This proprietary technology allows straightforward assay development for many challenging applications, such as detection of mutations or microsatellites and microbial genotyping.

The kit also includes CoralLoad--a buffer that contains two dyes that improves pipetting visibility during reaction setup, gel loading, and visualization of DNA migration. Therefore, it is no longer necessary to use other dyes for gel electrophoresis. Downstream analysis of the multiplex PCR products can be performed with a variety of methods such as agarose gels, capillary sequencers, as well as multicapillary electrophoresis with the QIAxcel advanced system.

The technology was developed by Qiagen (Venlo, The Netherlands), a leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA, and proteins from biologic samples such as blood or tissue. Assay technologies are used to make these isolated biomolecules visible.

Qiagen’s assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the first US Food and Drug Administration (FDA)-approved test for human papillomavirus (HPV), the primary cause of cervical cancer.

Related Links:

Qiagen



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
HPV Test
Allplex HPV28 Detection
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test

Latest BioResearch News

D-Serine May Predict Immune Checkpoint Therapy Resistance in Gastric Cancer
03 Aug 2011  |   BioResearch

New Genetic Cause Identified for Neurodevelopmental Disorder
03 Aug 2011  |   BioResearch

New Genetic Discovery Could Support Precision Diabetes Care
03 Aug 2011  |   BioResearch